Who owns SUPERNUS PHARMACEUTICALS, INC. (SUPN)? Elite investor 13F holders

5 tracked elite investors reported holding SUPERNUS PHARMACEUTICALS, INC as of 2026-06-30, including Renaissance Technologies LLC, D.E. Shaw, Third Avenue Management, Tudor Investment, Gotham Asset Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

5 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
Renaissance Technologies LLCSUPERNUS PHARMACEUTICALS INCSHARE2026-06-302026-08-13 00:00:0068750152.00 USD1478180.000000SharesreduceOriginal filing
D.E. ShawSUPERNUS PHARMACEUTICALS INCSHARE2026-06-302026-08-14 00:00:0035704239.00 USD767668.000000SharesaddOriginal filing
Third Avenue ManagementSUPERNUS PHARMACEUTICALS INCSHARE2026-06-302026-08-12 00:00:007103193.00 USD152724.000000SharesholdOriginal filing
Tudor InvestmentSUPERNUS PHARMACEUTICALS INCSHARE2026-06-302026-08-14 00:00:001150936.00 USD24746.000000SharesbuyOriginal filing
Gotham Asset ManagementSUPERNUS PHARMACEUTICALS INCSHARE2026-06-302026-08-14 00:00:00345197.00 USD7422.000000SharesbuyOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown